查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年人類胚胎幹細胞市場預測：按類型、來源、用途和地區分類的全球分析
市場調查報告書
商品編碼
1371999

2030 年人類胚胎幹細胞市場預測：按類型、來源、用途和地區分類的全球分析

Human Embryonic Stem Cells Market Forecasts to 2030 - Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球人類胚胎幹細胞市場規模為18億美元，預計在預測期內將以11.2%的年複合成長率成長，到2030年達到38億美元。

人類胚胎幹細胞是一種多功能細胞，由人類胚胎胚囊（通常是受精後 5 至 7 天）的內細胞團產生。這種細胞幾乎可以長成人體的任何細胞。它們不僅在人類早期發育中發揮重要作用，而且在再生醫學和研究中也具有巨大的應用潛力。為了確保使用人類胚胎幹細胞的療法的有效性和安全性，嚴格的品管程序以及對其製造和部署的安全性評估至關重要。

2022 年 8 月發表的一篇 DVC Stem報導證實，幹細胞治療帕金森氏症的目標是用健康、未分化的幹細胞取代受損的腦細胞。

技術進步不斷進步

人類胚胎幹細胞市場極大地受益於技術進步。這些進展顯著提高了人類胚胎幹細胞的功效、安全性和效用，使其成為潛在研究和治療應用更具吸引力的選擇。3D（3D）培養模型的發展使研究人員能夠更準確地重建人體內細胞的自然環境。因此，人類胚胎幹細胞已改善分化為用於再生治療的特定細胞類型。借助 CRISPR-Cas9 等技術創新，現在可以精確編輯 hESC 基因組，從而徹底改變了基因編輯領域。因此，上述所有要素都在推動市場成長。

對使用胚胎幹細胞的道德問題的擔憂

探索胚胎幹細胞（ESC）治療潛力的研究與許多道德困境有關，包括殺死人類胚胎。由於缺乏適當的政府立法來規範胚胎幹細胞治療方法開發的支持，最終可能會在一定程度上限制市場的成長。由於該領域法律的複雜性，需要進一步的聯邦立法來幫助研究人員、科學家和製藥公司開發並加速胚胎幹細胞治療方法的商業化。

慢性病增加

糖尿病、心血管疾病、神經系統疾病和自體自體免疫疾病等慢性疾病的罹患率不斷上升，增加了對有效治療方法的需求。這些疾病通常涉及永久性組織損傷，可以透過基於人類胚胎幹細胞的治療方法來治療。慢性疾病患者經常出現組織劣化和器官功能障礙，再生醫學技術利用它們來修復、替換和再生受損的組織和器官，從而解決慢性病的長期影響，是一種有用的資源。臨床研究已經開始確定使用人類胚胎幹細胞來治療某些慢性疾病的安全性和有效性。

免疫排斥傾向

免疫排斥會導致源自人類胚胎幹細胞的細胞療法失敗。如果接受者的免疫系統將移植的細胞識別為外來細胞，則移植的細胞可能會被攻擊和殺死，從而導致治療無效，並限制人類胚胎幹細胞治療的長期益處。益處可能有限。即使最初的植入是有效的，持續的免疫反應也會導致移植細胞逐漸流失，縮短治療效果的壽命，從而阻礙市場成長。

COVID-19 的影響

這場大流行擾亂了該研究所的研究項目，特別是幹細胞項目。一些研究機構的暫時關閉或縮減阻礙了人類胚胎幹細胞的研發和臨床試驗。此外，實驗室關閉、病患招募挑戰和安全問題減緩了這些臨床試驗的進展，並更加重視醫學研究和治療開發的安全性和有效性。因此，使用人類胚胎幹細胞的藥物將接受更徹底的安全評估，這可能會阻礙市場成長。

預計全能幹細胞領域在預測期內將是最大的。

全能幹細胞領域是一種特殊類型的幹細胞，具有有利的生長潛力，因為人體內所有類型的細胞，包括胚胎外和胚胎組織，都可以由這些細胞形成。全能幹細胞與全能幹細胞的不同之處在於，全能幹細胞可以發展成除胚外組織外的所有體細胞。使用這些細胞的研究有助於了解全能幹細胞如何發展成不同的細胞類型。

幹細胞生物學研究領域預計在預測期內將出現最高的年複合成長率。

幹細胞生物學研究領域預計在預測期內年複合成長率最高。各種類型的幹細胞也用於醫學。許多生物製藥公司最近對這些化合物進行了大量研究，這些化合物對多種疾病有大量的階段用途，包括癌症和神經系統疾病。隨著帕金森氏症和癌症等疾病發生率的增加，幹細胞生物學研究預計未來將進一步發展。由於這些原因，預計所研究的市場將在預測期內顯著成長。

比最大的地區

除了政府對藥物研發、醫療保健投資以及在藥物研發技術開發的先進基礎設施方面取得進展的重視外，由於該地區多家公司擴大發展戰略，北美正在經歷快速成長。在預測期內佔據最大的市場佔有率。此外，藥物研究和相關臨床研究的嚴格法規規則預計將提振市場。在美國，生物製藥製造商正在推出生物製藥和生物相似藥產品，這是預計支持市場擴張的另一個要素。

複合年複合成長率最高的地區：

由於歐洲對人類胚胎幹細胞用於研究和治療的使用有嚴格的法律法規，預計在預測期內複合年複合成長率最高。使用幹細胞開發和核准藥物受到國家法規機構和歐洲藥品管理局 (EMA) 的法規。例如，在歐洲，利用人類胚胎幹細胞治療多種疾病的臨床研究已經且目前正在進行中，包括脊髓損傷、心臟病和退化性疾病。這些臨床試驗的目的是評估基於幹細胞的治療的有效性和安全性。該地區學術機構、生物技術公司和醫療機構之間的合作很常見，以推進人類胚胎幹細胞的研究和實用化，從而推動市場發展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球人類胚胎幹細胞市場：依類型

  • 全能幹細胞
  • 多功能細胞
  • 多能幹細胞
  • 寡能幹細胞
  • 單能幹細胞
  • 其他類型

第6章 全球人類胚胎幹細胞市場：依來源分類

  • 骨髓
  • 成人身體組織
  • 胚胎組織
  • 胎兒組織
  • 分化的體細胞
  • 其他資訊來源

第7章 全球人類胚胎幹細胞市場：依用途

  • 幹細胞生物學研究
  • 再生醫學
  • 人體組織工程
  • 毒性試驗
  • 血液疾病的治療
  • 心血管疾病的治療
  • 其他用途

第8章 全球人類胚胎幹細胞市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • PeproTech Inc.
  • Astellas Pharma Inc.
  • Merck KGaA
  • Lineage Cell Therapeutics Inc.
  • PromoCell GmbH
  • Thermo Fisher Scientific
  • ViaCyte, Inc.
  • Takara Bio Inc.
  • STEMCELL Technologies Inc
  • Cell Cure Neurosciences LTD
  • CellGenix GmbH
  • ESI BIO
  • Lonza
  • Kite Pharma
  • Cynata
  • Sumanas, Inc.
  • LifeCell
  • International Stem Cell Corporation
  • Genea BioCells
  • Geron
Product Code: SMRC24055

According to Stratistics MRC, the Global Human Embryonic Stem Cells Market is accounted for $1.8 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 11.2% during the forecast period. The inner cell mass of a human embryo during the blastocyst stage, usually 5-7 days after conception, is when human embryonic stem cells, a kind of pluripotent stem cell, are generated. The amazing capacity of these cells to develop into almost any form of cell in the human body is well recognized. They have a tremendous potential for application in regenerative medicine and research in addition to playing a critical function in early human development. It is crucial to ensure the efficacy and security of human embryonic stem-based therapeutics, to produce and deploy them, rigorous quality control procedures and safety evaluations are essential.

According to the article from DVC Stem published in August 2022, it was observed that the goal of stem cell therapy for Parkinson's disease is to replace destroyed brain cells with healthy, undifferentiated stem cells.

Market Dynamics:

Driver:

Growing technological advancements

The market for human embryonic stem cells has greatly benefited from technological improvements. With these developments, working with these cells has substantially improved in terms of effectiveness, safety, and usability, making them a more attractive alternative for research and possible therapeutic applications. Researchers can more accurately replicate the natural milieu of cells in the human body thanks to the development of three-dimensional (3D) culture models. As a result, human embryonic stem cells differentiation into certain cell types for regenerative therapy is improved. With the help of innovations like CRISPR-Cas9, the hESC genome may now be precisely edited, revolutionizing the field of gene editing. Hence all the above factors boost the market growth.

Restraint:

Concerns about the ethics of using embryonic stem cells

Studies looking into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of moral dilemmas including the killing of human embryos. Lack of appropriate government laws that specify what can be supported in the development of therapies using embryo-based stem cells may eventually limit the market's growth to some extent. Federal laws are further necessary due to the complexity of the legislation in this field so that researchers, scientists, and pharmaceutical firms can develop ESC treatment and accelerate its commercialization.

Opportunity:

Rising incidence of chronic diseases

There is a high demand for efficient therapies due to the rising prevalence of chronic diseases including diabetes, cardiovascular disease, neurological disorders, and autoimmune ailments. These diseases, which frequently include permanent tissue damage, may be treated using human embryonic stem cells -based therapy. Tissue deterioration and organ dysfunction are frequently seen in patients with chronic illnesses and are a useful resource for tackling the long-term effects of chronic illnesses because regenerative medicine techniques use them to repair, replace, or regenerate damaged tissues and organs. To determine the safety and effectiveness of human embryonic stem-based treatments for particular chronic conditions, clinical studies have been started.

Threat:

Tendency of immune rejection

Immune rejection may cause human embryonic stem cells-derived cell treatments to fail. Transplanted cells may be attacked and killed if the immune system of the recipient recognizes them as alien, making the therapy useless and it may limit the long-term advantages of therapy based on human embryonic stem cells. Even if the initial engraftment is effective, the persistent immune response may cause the transplanted cells to gradually disappear, decreasing the therapeutic effect's longevity thus hampering the market growth.

COVID-19 Impact

The pandemic interfered with laboratory research projects, particularly stem cell projects. The development of human embryonic stem cells research and clinical trials was hampered by the temporary closure or reduction of activities at several research organizations. Moreover, the progress of these trials was slowed down by site closures, challenges with patient recruiting, and safety worries and made safety and efficacy of medical research and therapy development even more important. This might result in human embryonic stem cells -based medicines receiving more thorough safety evaluations which hinder the market growth.

The totipotent stem cells segment is expected to be the largest during the forecast period

The totipotent stem cells segment is estimated to have a lucrative growth, as these are special kind of stem cell and all cell types in the human body, including extraembryonic and embryonic tissues, may be formed from these cells, which is extraordinary. They vary from pluripotent stem cells, though, in that the latter can develop into all bodily cell types except for extraembryonic tissues. Understanding how totipotent stem cells develop into distinct cell types can be aided by research employing these cells.

The stem cell biology research segment is expected to have the highest CAGR during the forecast period

The stem cell biology research segment is anticipated to witness the highest CAGR growth during the forecast period, as these are living things that can develop into many kinds of cells. Various stem cell types are also employed in medical treatments. Numerous biopharmaceutical firms have recently conducted substantial research into these compounds, which have numerous uses at the clinical stage for a variety of disorders, including cancer and neurological ailments. Due to the growing frequency of disorders like Parkinson's disease, cancer, and others, stem cell biology research will see improved growth. The market under study is thus anticipated to see a significant growth rate throughout the projected period as a result of these reasons.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the growing government emphasis on drug discovery, healthcare investment, and advanced infrastructure for the development of technologies in drug discovery, as well as expanding development strategies used by several business verticals in the area. Furthermore, it is predicted that strict regulatory rules for medication research and related clinical studies would spur the market. The launch of biological and bio similar drugs by biopharmaceutical manufacturers in the US is another factor that is anticipated to fuel the market's expansion.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to stringent laws governing the use of human embryonic stem cells for both research and therapy. The creation and endorsement of stem cell-based medicines are regulated by national regulatory organizations and the European Medicines Agency (EMA). For instance, in Europe, human embryonic stem cells -based clinical studies have been carried out or are now being done for a range of illnesses, including spinal cord injury, heart disease, and degenerative diseases. The purpose of these trials is to assess the efficacy and safety of stem cell-based treatments. To advance human embryonic stem cells research and turn it into practical applications, partnerships between academic institutions, biotech firms, and healthcare facilities are typical in this region which encourages the market.

Key players in the market:

Some of the key players profiled in the Human Embryonic Stem Cells Market include: PeproTech Inc., Astellas Pharma Inc., Merck KGaA, Lineage Cell Therapeutics Inc., PromoCell GmbH, Thermo Fisher Scientific, ViaCyte, Inc., Takara Bio Inc., STEMCELL Technologies Inc, Cell Cure Neurosciences LTD, CellGenix GmbH, ESI BIO, Lonza, Kite Pharma, Cynata, Sumanas, Inc., LifeCell, International Stem Cell Corporation, Genea BioCells and Geron

Key Developments:

In October 2023, Astellas Pharma Inc. and BioLabs Global, Incand Mitsui Fudosan, announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.

In October 2023, Merck launches new collaboration with United Nations-Guided Global Initiative on ageing to support carers; new training course provides critical skills for unpaid family carers and coincides with European Carers Day and Family Caregiver awareness month in the U.S.

In September 2023, Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

In September 2023, Thermo Fisher Scientific Inc. the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF's Alliance for Representative Clinical Trials (ARC).

Types Covered:

  • Totipotent Stem Cells
  • Pluripotent Stem Cells
  • Multipotent Stem Cells
  • Oligopotent Stem Cells
  • Unipotent Stem Cells
  • Other Types

Sources Covered:

  • Bone Marrow
  • Adult Body Tissues
  • Embryonic Tissues
  • Fetal tissues
  • Differentiated Somatic Cells
  • Other Sources

Applications Covered:

  • Stem Cell Biology Research
  • Regenerative Medicine
  • Tissue Engineering
  • Toxicology Testing
  • Blood Disease Treatment
  • Treatment of Cardiovascular Disease
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Embryonic Stem Cells Market, By Type

  • 5.1 Introduction
  • 5.2 Totipotent Stem Cells
  • 5.3 Pluripotent Stem Cells
  • 5.4 Multipotent Stem Cells
  • 5.5 Oligopotent Stem Cells
  • 5.6 Unipotent Stem Cells
  • 5.7 Other Types

6 Global Human Embryonic Stem Cells Market, By Source

  • 6.1 Introduction
  • 6.2 Bone Marrow
  • 6.3 Adult Body Tissues
  • 6.4 Embryonic Tissues
  • 6.5 Fetal tissues
  • 6.6 Differentiated Somatic Cells
  • 6.7 Other Sources

7 Global Human Embryonic Stem Cells Market, By Application

  • 7.1 Introduction
  • 7.2 Stem Cell Biology Research
  • 7.3 Regenerative Medicine
  • 7.4 Tissue Engineering
  • 7.5 Toxicology Testing
  • 7.6 Blood Disease Treatment
  • 7.7 Treatment of Cardiovascular Disease
  • 7.8 Other Applications

8 Global Human Embryonic Stem Cells Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 PeproTech Inc.
  • 10.2 Astellas Pharma Inc.
  • 10.3 Merck KGaA
  • 10.4 Lineage Cell Therapeutics Inc.
  • 10.5 PromoCell GmbH
  • 10.6 Thermo Fisher Scientific
  • 10.7 ViaCyte, Inc.
  • 10.8 Takara Bio Inc.
  • 10.9 STEMCELL Technologies Inc
  • 10.10 Cell Cure Neurosciences LTD
  • 10.11 CellGenix GmbH
  • 10.12 ESI BIO
  • 10.13 Lonza
  • 10.14 Kite Pharma
  • 10.15 Cynata
  • 10.16 Sumanas, Inc.
  • 10.17 LifeCell
  • 10.18 International Stem Cell Corporation
  • 10.19 Genea BioCells
  • 10.20 Geron

List of Tables

  • Table 1 Global Human Embryonic Stem Cells Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 4 Global Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 5 Global Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 6 Global Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 7 Global Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 8 Global Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 10 Global Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 11 Global Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 12 Global Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 13 Global Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 14 Global Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 15 Global Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 16 Global Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 18 Global Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 19 Global Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 20 Global Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 21 Global Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 22 Global Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 23 Global Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 North America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 27 North America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 28 North America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 29 North America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 30 North America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 31 North America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 32 North America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 33 North America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 34 North America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 35 North America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 36 North America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 37 North America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 38 North America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 39 North America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 North America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 41 North America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 42 North America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 43 North America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 44 North America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 45 North America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 46 North America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 47 Europe Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 50 Europe Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 51 Europe Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 52 Europe Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 53 Europe Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 54 Europe Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 Europe Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 56 Europe Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 57 Europe Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 58 Europe Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 59 Europe Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 60 Europe Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 61 Europe Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 62 Europe Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 63 Europe Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 64 Europe Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 65 Europe Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 66 Europe Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 67 Europe Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 68 Europe Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Europe Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 77 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 79 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 80 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 81 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 82 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 83 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 84 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 85 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 86 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 87 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 88 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 89 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 90 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 91 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 92 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 93 South America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 96 South America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 97 South America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 98 South America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 99 South America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 100 South America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 101 South America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 102 South America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 103 South America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 104 South America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 105 South America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 106 South America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 107 South America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 108 South America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 109 South America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 110 South America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 111 South America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 112 South America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 113 South America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 114 South America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 115 South America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 116 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 119 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 120 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 121 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 122 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 123 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 124 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 125 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 126 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 127 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 128 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 129 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 130 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 131 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 132 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 133 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 135 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 136 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 137 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 138 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)